Visen Pharmaceutical HK$783.3 million IPO
The shares are listed on the HKEX
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Guotai Junan merger with Haitong and concurrent placement of shares
We advised Guotai Junan Securities on the transaction, creating the largest securities company in China
MIXUE HK$3.45 billion IPO
We advised MIXUE on its IPO and HKEX listing
iQIYI $350 million convertible notes offering and concurrent private repurchases
We advised iQIYI on the transactions
Mizuho Financial Group $1.9 billion senior notes offering
The offering included fixed-to-fixed reset rate notes and floating-rate notes
Kioxia Holdings ¥120.4 billion IPO
The shares are listed on the Tokyo Stock Exchange
Sanrio ¥135.1 billion secondary offering
The shares are listed on the Tokyo Stock Exchange
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
Rakuten Group $550 million subordinated notes offering
The 8.125% reset notes are listed on the Singapore Exchange
SMFG $3.2 billion senior notes offering
We advised SMFG on its SEC-registered offering of TLAC notes